Showing 1,041 - 1,060 results of 48,685 for search '(( 50 ((ng decrease) OR (a decrease)) ) OR ( 5 ((mg decrease) OR (mean decrease)) ))', query time: 1.33s Refine Results
  1. 1041
  2. 1042
  3. 1043
  4. 1044

    LPS-induced decrease in Sp1 DNA binding activity is associated with an increased NF-κB binding activity. by Xiaobing Ye (49295)

    Published 2015
    “…(B) and (D): The EMSA Sp1 and NF-B bands were quantified using densitometry, and expressed as x10<sup>5</sup> pixels. Mean ± SEM of 4 mice per group. *, p < 0.05, compared to control groups (one way ANOVA).…”
  5. 1045
  6. 1046
  7. 1047
  8. 1048
  9. 1049
  10. 1050

    Supplementary Material for: Fasting blood glucose: A mediator of the association between estimated glomerular filtration rate and arterial stiffness in Japanese population with dec... by Wu L. (4145662)

    Published 2024
    “…The mean values for FBG, eGFR and baPWV were 5.46 ± 0.79 mmol/L, 68.83 ± 10.05 mL/min/1.73m², and 1423.50 ± 247.78 cm/s, respectively. …”
  11. 1051

    Decreased methylglyoxal-mediated protein glycation in the healthy aging mouse model of ectopic expression of UCP1 in skeletal muscle by Jinit, Masania

    Published 2023
    “…This may be achieved by decreasing protein glycation by the reactive metabolite, methylglyoxal (MG). …”
    Get full text
    Get full text
    Get full text
    article
  12. 1052
  13. 1053

    The novel <i>carboxylesterase 1</i> variant c.662A>G may decrease the bioactivation of oseltamivir in humans by Jaeseong Oh (3947381)

    Published 2017
    “…A novel <i>CES1</i> c.662A>G single nucleotide polymorphism (SNP) was predicted to decrease CES1 enzymatic activity in an <i>in silico</i> analysis. …”
  14. 1054

    Complete data. by Jan Víteček (11434774)

    Published 2024
    “…The rt-PA became increasingly less efficient for clots larger than 50 μl at a clinically relevant concentration of 1.3 mg/l. …”
  15. 1055

    Fig 4 - by Jan Víteček (11434774)

    Published 2024
    “…The rt-PA became increasingly less efficient for clots larger than 50 μl at a clinically relevant concentration of 1.3 mg/l. …”
  16. 1056

    The NK1-receptor antagonist ezlopitant significantly decreases voluntary intake of sucrose using the drinking in the dark model in mice. by Pia Steensland (362091)

    Published 2013
    “…<p>The highest dose of ezlopitant (15 mg/kg) decreased consumption of 5% sucrose (<b>A</b>). …”
  17. 1057
  18. 1058
  19. 1059
  20. 1060